A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ

Inclusion Criteria:

* Histologically confirmed DCIS by breast core biopsy with a corresponding lesion on breast MRI of at least 1-cm3 in volume.
* Patients may have undergone treatment with prior chemotherapy if this was greater than 12 months prior to current diagnosis.
* Age \>18 years.
* ECOG performance status \<2 (Karnofsky \>60%)
* Life expectancy of greater than 12 months.
* Normal organ and marrow function as defined below:
* leukocytes \>3,000/mcL
* absolute neutrophil count \>1,500/mcL
* platelets \>100,000/mcL
* total bilirubin within normal institutional limits
* AST(SGOT) \& ALT(SGPT)within normal institutional limits
* creatinine \<1.5 times institutional upper limit of normal or creatinine clearance \>60 mL/min/1.73 m2
* Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Pregnancy
* Patients who have undergone prior excisional biopsy for DCIS.
* Patients who are unable to undergo MRI due to claustrophobia or other reason.
* Patients with ipsilateral treatment for DCIS or breast cancer within 12 months prior to entering this study.
* Patients receiving any other chemotherapy or investigational agents.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to green tea extracts or sensitivity to green tea.
* Uncontrolled concurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.